BioXcel Therapeutics files prospectus supplement for up to $80M ATM stock offering

BioXcel Therapeutics, Inc.

Filed prospectus supplement to sell up to $80M of common stock via ATM program with Canaccord Genuity.
ATM program established April 3, 2025; supplement filed August 18, 2025.
Honigman LLP issued validity opinion on shares; counsel's opinion filed as Exhibit 5.1.
Shares to be sold through any method deemed an 'at the market' offering under Rule 415(a)(4).

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.